Chronic vulvovaginal candidiasis: new look at old problem

Authors

  • Т. Ф Татарчук Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • Л. В. Калугина Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine, Ukraine
  • И. Н. Шакало Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.22.34-39

Keywords:

vulvovaginal candidiasis, fenticonazole, Lomexin®

Abstract

The study on the effectiveness of fenticonazole treatment in 60 patients aged 18 to 45 years old with chronic recurrent vulvovaginal candidiasis was performed. Women were divided into two equal groups of 30 people. The main group received fenticonazole (drug Lomexin®) for 6 days (the sexual partners of women in the same period was recommended cream fenticonazole). The comparison group was administered ketoconazole for 10 days and treatment of sexual partners according to generally accepted recommendations.

The results showed a high (96.67%) an anti-recurrence effect of Lomexin® local therapy of chronic vulvovaginal candidiasis compared with ketoconazole (80.0%). These results allow the authors to recommend the scheme of fenticonazole local therapy for chronic vulvovaginal candidiasis

Author Biographies

Т. Ф Татарчук, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, professor, corresponding member. NAMS of Ukraine, Deputy Director for Research, Head of Endocrine Gynecology

Л. В. Калугина, Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine

MD, Endocrine Gynecology Department

И. Н. Шакало, Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine

PhD, researcher of Endocrine Gynecology Department

References

  1. Zaporozhan, V.N., Tatarchuk, T.F., Dubinina, V.G., Kosei, N.V. “Modern diagnostics and treatment of endometrial hyperplastic processes.” Reproductive Endocrinology, 1(3) (2012): 5–12.
  2. Infections in obstetrics and gynecology. / Ed. by O.V. Makarov, V.A. Aleshkin, T.N. Savchenko. Moscow. MEDpress-inform (2007): 464 p.
  3. Kalugina, L.V., Tatarchuk, T.F. “Endometrial polyps. Are we need preventive treatment?” Reproductive Endocrinology, 2 (10) (2013): 69–75.
  4. Senchuk, A.Y., Doskoch, I.O., Martynova, D.A., Savrun, S.S. “New opportunities in the treatment of vegetative forms of yeast Candida in patients with mixed vulvovaginitis.” Women’s Health, 8(74) (2012): 1–4.
  5. Radzinskiy, V.E., Artymuk, N.V., Berlev, I,V., et al. “A randomized multicenter study of efficacy 600 and 1200 mg Lomexin treatment of vulvovaginal candidiasis in women of reproductive age.” Obstetrics and Gynecology, 2(2013): 113–118.
  6. Kosei, N.V. “Modern principles of treatment of inflammatory diseases of the female genital organs.” Reproductive Endocrinology, 1(9) (2013): 78-85.
  7. Fernаndez-Alba, J., Valle-Gay, A., Dibildox, M., Vargas, J.A., Gonzаlez, J., Garcнa, M., Lуpez, L.H. and the Fentimex Mexican Study Group. “Fenticonazole nitrate for treatment of vulvovaginitis: efficacy, safety, and tolerability of 1-gram ovules, administered as ultrashort 2-day regimen.” J Chemother, 16(2004): 179–86.
  8. Hauptmann, S., Kohler, G. “Etiology, Pathogenesis, and Malignant Potential of Uterine Leiomyoma – A Review.” Curr Obstet Gynecol Rep, 3(2014): 186–190.
  9. Kovachev, S., Nacheva, A., Vacheva-Dobrevska, R., Vasilev, N. “Combined single-day treatment in acute vulvovaginal candidosis.” Akush Ginekol (Sofiia), 48(6) (2009): 18–23.
  10. M archaim, D., Lemanek, L., Bheemreddy, S., Kaye, K.S., Sobel, J.D. “Fluconazole-Resistant Candida albicans Vulvovaginitis.” Obstetrics and Gynecology, 6(2012) (Vol. 120): 1407–1414.
  11. M unoz Reyes, J.R., Villanueva Reynoso, C., Ramos, C.J., Menendez Vazquez, J., Bailon Uriza, R., Vargas, A.J. “Efficacy and tolerance of 200 mg fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis.” Ginecol Obstet Mex, 70(2002): 59–65.
  12. P eters, B.M., Yano, J., Noverr, M.C., Fidel, P.L. Jr. “Candida Vaginitis: When Opportunism Knocks, the Host Responds.” PLoS Pathog, 10(4) (2014): e1003965.
  13. P eters, B.M., Palmer, G.E., Fidel, P.L. Jr, Noverr, M.C. “Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida vaginitis.” Infect Immun, 82(2014): 532–543.
  14. Gandhi, T.N., Patel, M.G., Mannu, R. “Jain Prospective study of vaginal discharge and prevalence of vulvovaginal candidiasis in a tertiary care hospital.” IJCRR, 7(1) (2015): 34–38.
  15. Ziegler, D., Borghese, B. “Endometriosis and infertility: pathophysiology and management Review Article.” The Lancet, 9742(2010) (Vol. 376): 730–738.

Downloads

Published

2015-04-14

How to Cite

Татарчук, Т. Ф., Калугина, Л. В., & Шакало, И. Н. (2015). Chronic vulvovaginal candidiasis: new look at old problem. REPRODUCTIVE ENDOCRINOLOGY, (22), 34–39. https://doi.org/10.18370/2309-4117.2015.22.34-39

Issue

No. 22 (2015)

Section

Inflammatory diseases

License

Copyright (c) 2015 Т. Ф Татарчук, Л. В. Калугина, И. Н. Шакало

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.